Pancreatic Cancer Research

ResearcherTufts UniversityNo recent work listed

Timothy Louis Fitzgerald

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7350-1269; OpenAlex author ID A5102917326. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
10
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 5 papers

Papers 10

  1. Preoperative downstaging of pancreatic cancer is associated with improved survival after multi-agent chemotherapy, but not after radiation. Last author DOI 10.1016/j.suronc.2023.101939↗
  2. Improved Overall Survival of Patients with Pancreatic Cancer through Multiagent Chemotherapy and Increased Rates of Surgical Resection. Last author DOI 10.1177/00031348221148350↗
  3. Pancreatic Cancer with Vascular Involvement: Adherence to Current Standard-of-Care Associated with Improved Survival. Last author DOI 10.1177/00031348231156756↗
  4. Contemporary Treatment Paradigms are Associated with Improved Survival in Pancreatic Cancer. Last author DOI 10.1177/00031348231157897↗
  5. Pathologic Tumor Regression is Associated With Improved Survival in Pancreatic Cancer. Last author DOI 10.1177/00031348231175120↗
  6. Multiscale anisotropy analysis of second-harmonic generation collagen imaging of human pancreatic cancer. Co-author DOI 10.3389/fonc.2022.991850↗
  7. Upfront resection versus neoadjuvant therapy for T1/T2 pancreatic cancer. Last author DOI 10.1016/j.hpb.2020.06.010↗
  8. Better Defining the Role of Total Neoadjuvant Radiation: Changing Paradigms in Locally Advanced Pancreatic Cancer. Last author DOI 10.1245/s10434-019-07584-5↗
  9. Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells. Co-author DOI 10.1016/j.jbior.2015.06.003↗
  10. Pancreatic cancer stem cells: association with cell surface markers, prognosis, resistance, metastasis and treatment. Co-author DOI 10.1016/j.jbior.2014.05.001↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Laura M. Nicolais · 5 shared papers, 2023 · strength 1.27
  2. Abdimajid Mohamed BS · 4 shared papers, 2023 · strength 1.00
  3. Roberto J. Vidrí · 2 shared papers, 2019–2021 · strength 0.32
  4. Bridget N. Kelly · 1 shared paper, 2023 · strength 0.26
  5. André Khalil · 1 shared paper, 2022 · strength 0.17
  6. Joshua Hamilton · 1 shared paper, 2022 · strength 0.17
  7. James Andrew McCubrey · 2 shared papers, 2014–2015 · strength 0.14
  8. Saverio Candido · 1 shared paper, 2015 · strength 0.05
  9. Stephen Lee Abrams · 1 shared paper, 2015 · strength 0.05
  10. Melchiorre Cervello · 1 shared paper, 2015 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.